Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI + Bevacizumab +/- QL1706 in 2nd-Line Metastatic Colorectal Cancer
NCT07729605Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised trial of QL1706 in colorectal cancer (CRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07729605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729605.